Welcome to our dedicated page for Affimed news (Ticker: AFMD), a resource for investors and traders seeking the latest updates and insights on Affimed stock.
Affimed N.V. (AFMD) has been a Nasdaq-listed, clinical-stage immuno-oncology company focused on innate cell engagers (ICE®) generated on its proprietary ROCK® platform. Company news has highlighted how these ICE® molecules are being developed to recognize and kill a range of hematologic and solid tumors by engaging innate immune cells.
News coverage for AFMD includes detailed clinical updates on key ICE® programs such as AFM24, AFM28 and acimtamig (AFM13). Releases describe AFM24 as a tetravalent, bispecific ICE® targeting CD16A and EGFR, with data in advanced or metastatic non-small cell lung cancer, including combinations with atezolizumab. For AFM28, Affimed has reported early Phase 1 results in relapsed/refractory acute myeloid leukemia, including composite complete remission rates and safety findings. Additional news has covered acimtamig in combination with AlloNK® (AB-101) in classical Hodgkin lymphoma, with abstracts accepted for major oncology meetings.
Another important category of AFMD news relates to corporate and listing developments. In May 2025, Affimed announced that it had filed for insolvency proceedings in Mannheim, Germany, citing overindebtedness and liquidity concerns. Shortly thereafter, the company disclosed that Nasdaq staff would suspend trading of its common shares and proceed with a delisting process, culminating in a Form 25 filing to remove its common stock from Nasdaq listing and registration.
On this news page, readers can review historical press releases on AFMD’s clinical trial data, conference presentations, investor webcasts, and regulatory and listing updates. For those tracking the company’s ICE® pipeline and its insolvency and delisting process, this archive offers a centralized view of how Affimed’s scientific, clinical, and corporate story has evolved over time.
Affimed N.V. (Nasdaq: AFMD) has established a Scientific Advisory Board (SAB) composed of leading experts in immuno-oncology to guide its innate cell engagers (ICE®) programs. This advisory board includes renowned figures such as Stephen M. Ansell and Todd A. Fehniger, who will provide insights into cancer therapies. The SAB aims to enhance Affimed's development strategy and evaluate emerging technologies. Chief Scientific Officer Dr. Arndt Schottelius emphasized the board's vital expertise in advancing their promising pipeline of therapies designed to leverage the innate immune system against cancer.
Affimed N.V. (Nasdaq: AFMD) showcased promising preclinical data for its bispecific innate cell engager, AFM28, targeting CD123 in treating relapsed/refractory acute myeloid leukemia (AML) at the EHA Annual Meeting. AFM28 demonstrated potent anti-tumor activity against CD123-positive cells, even at low expression levels, while sparing healthy cells. In vivo studies indicated strong anti-tumor efficacy and a favorable safety profile. A first-in-human phase 1 clinical trial is set to commence in the second half of 2022, aiming to assess AFM28’s safety and efficacy as a monotherapy and in combination with NK cell therapies.
Affimed N.V. (Nasdaq: AFMD) reported its first quarter 2022 financial results and clinical updates. The REDIRECT study for AFM13 monotherapy completed enrollment, with topline data expected in Q4 2022. At AACR 2022, AFM13 showed a 100% objective response rate and a rise in complete responses. The cash position is strong, with €257.5 million expected to support operations into mid-2024. However, net loss for Q1 2022 was €16.7 million, down from a profit a year ago, while R&D expenses surged by 61% to €18.4 million, indicating increased investment in their product pipeline.
Affimed (Nasdaq: AFMD) announced three clinical trial designs for its AFM24 innate cell engager (ICE®), showcased at the ASCO Annual Meeting from June 3-7, 2022. The trials include AFM24 monotherapy and combinations with atezolizumab and SNK01 autologous NK cells, targeting advanced EGFR-expressing solid tumors. AFM24 aims to activate the innate immune system, showing a well-managed safety profile and established recommended phase 2 dose (RP2D) of 480 mg. These innovative approaches represent potential advancements in treatment for patients resistant to current therapies.
Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company, announced that CEO Dr. Adi Hoess will present at the 2022 Jefferies Healthcare Conference on June 8, 2022, at 1:00 PM EDT. The presentation will focus on Affimed's commitment to empowering the innate immune system to fight cancer. A live webcast will be available on Affimed's website, with a replay accessible for 30 days post-event. For inquiries about the conference or to schedule meetings, interested parties can contact Jefferies or reach out to Alex Fudukidis.
Affimed N.V. (Nasdaq: AFMD) announced that its 2022 Annual General Meeting of Shareholders will take place on June 22, 2022, at 09:00 a.m. CET in Amsterdam. The meeting aims to discuss company performance and future strategies. Shareholders can access the notice and agenda on Affimed's website or through the SEC's site. Affimed focuses on immuno-oncology, leveraging its proprietary ROCK® platform to develop innovative therapies targeting various cancers. The company is committed to enhancing patients' innate ability to combat cancer.
Affimed N.V. (Nasdaq: AFMD) announced it will release its Q1 2022 financial results and provide a corporate update on June 1, 2022. A conference call will take place at 8:30 a.m. EDT, available via phone and webcast. The call can be accessed by dialing +1 (409) 220-9054 for U.S. participants and +44 (0) 8000 323836 for international callers, using conference ID 4440407. Affimed focuses on immuno-oncology and utilizes its proprietary ROCK® platform to develop innovative cancer therapies.
Affimed N.V. (Nasdaq: AFMD) presented new data on AFM24 and AFM28 at the NK2022 conference, highlighting their potential in cancer treatment. The AFM24 data showed its efficacy as a CD16A/EGFR-targeting bispecific innate cell engager, stimulating anti-cancer immunity in patients with EGFR-expressing tumors. Meanwhile, AFM28 demonstrated anti-leukemic effects when combined with NK cells, suggesting it could offer an off-the-shelf therapy for AML and MDS patients. Both compounds are currently undergoing phase 1/2a clinical studies.
Affimed N.V. (Nasdaq: AFMD) announced the upcoming first-in-human phase 1 study of its bispecific innate cell engager AFM28, targeting CD123 in patients with relapsed/refractory acute myeloid leukemia (AML). This innovative therapy showed promising results in preclinical studies, effectively destroying CD123-positive tumor cells while sparing healthy cells. Toxicology models indicated low risks of side effects such as cytokine release syndrome. The study is set to begin in the second half of 2022, with a poster presentation scheduled at the EHA Annual Meeting in June 2022.
Affimed N.V. (Nasdaq: AFMD) announced that the American Society of Clinical Oncology (ASCO) has removed the oral presentation of the AFM13-104 trial from its conference program. This decision was due to ASCO's embargo policy, following the recent data presentation at the AACR Annual Meeting on April 10, 2022. Affimed clarified that this removal is unrelated to the ongoing trial's status or results. The company is collaborating with The University of Texas MD Anderson Cancer Center to submit additional data on AFM13-104 to a future scientific forum.